To the Editor We read the article by Harding and colleagues1 regarding escalation vs early intensive approaches in treating patients with multiple sclerosis (MS). We agree that treating MS early and aggressively to halt disease from the start sounds attractive. In fact, there are clinical trial data that find an association of an early vs delayed start of a higher-efficacy therapy with sustained relapse rate reductions.2 However, there are limitations in interpreting observational data, especially in MS cohorts, that were not fully addressed in the article.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Soares-dos-Reis R, Messina S. Cautious Interpretation of Observational Data. JAMA Neurol. Published online October 14, 2019. doi:https://doi.org/10.1001/jamaneurol.2019.3456
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: